碳青霉烯类抗生素耐药菌的治疗选择

Treatment options for carbapenem-resistant bacteria

多重耐药菌在全球范围内的快速增长和流行日益严重,给临床治疗带来严峻挑战,直接影响患者预后,造成严重的社会和经济负担。最严重的泛耐药菌铜绿假单胞菌、产碳青霉烯酶肺炎克雷伯菌和鲍曼不动杆菌使抗生素的治疗选择濒临绝望的境地。为应对多重耐药菌,在加强耐药监测指导临床治疗的同时,也在不断探讨新的治疗措施。本文对目前国内外碳青霉烯类抗生素耐药菌的流行状况和治疗新进展进行阐述。

Nowadays, the rapid growth and prevalence of multi-drug resistant（MDR） bacteria in the global scope have been taken the challenge for the treatment of infectious diseases. Meantime MDR has brought direct impact on the prognosis of the patients and caused serious social and economic burden. The most serious extensive drug resistant（XDR） bacteria Pseudomonas aeruginosa,Klebsiella pneumoniaand and Acinetobacter baumanii force us unable to choose antibiotics for treating the patients with MDR infections. In order to deal with the MDR, we need focus on drug-resistant surveillance to guide clinical treatment and management, alsoexplore new therapeutic measures constantly. We perform a review of the development in epidemiology and treatment of carba-penem-resistant bacteria.